BeiGeneBGNE
About: BeiGene Ltd is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. BeiGene's key cancer treatments are BRUKINSA (zanubrutinib), Bruton's tyrosine kinase (BTK) inhibitor, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody. In addition, it has a diverse pipeline of novel therapeutics focusing on a range of malignancies, including AML, MDS, multiple myeloma, lung, gastrointestinal, breast, and gynecologic cancers. The Company operates in one segment: pharmaceutical products and is primarily located in the U.S. and the PRC. Key revenue is generated from the U.S.
Employees: 10,000
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
31% more call options, than puts
Call options by funds: $18.6M | Put options by funds: $14.2M
11% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 65
0.02% more ownership
Funds ownership: 3.72% [Q1] → 3.74% (+0.02%) [Q2]
3% less funds holding
Funds holding: 200 [Q1] → 195 (-5) [Q2]
8% less capital invested
Capital invested by funds: $7.28B [Q1] → $6.67B (-$606M) [Q2]
20% less funds holding in top 10
Funds holding in top 10: 10 [Q1] → 8 (-2) [Q2]
21% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 24
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
JMP Securities Reni Benjamin 25% 1-year accuracy 5 / 20 met price target | 36%upside $288 | Market Outperform Initiated | 18 Sept 2024 |
JP Morgan Jessica Fye 64% 1-year accuracy 25 / 39 met price target | 6%downside $200 | Overweight Maintained | 20 Aug 2024 |
Citigroup Yigal Nochomovitz 53% 1-year accuracy 18 / 34 met price target | 36%upside $288 | Buy Maintained | 8 Aug 2024 |
Financial journalist opinion
Based on 5 articles about BGNE published over the past 30 days